3-chloro-4-isobutoxy-benzonitrile | 1035217-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-chloro-4-isobutoxy-benzonitrile
• 英文别名: 3-Chloro-4-isobutoxybenzonitrile；3-chloro-4-(2-methylpropoxy)benzonitrile
• CAS: 1035217-34-5
• 化学式: C₁₁H₁₂ClNO
• mdl: MFCD14645151
• 分子量: 209.675
• InChiKey: FXXYOMRPRRWPEU-UHFFFAOYSA-N

物化性质

• 沸点：
  304.5±22.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁醇 、 3-氯-4-溴苯腈 在 copper(l) iodide 、 N-([1,1'-biphenyl]-2-yl)-N′-(2-phenylnaphthalen-1-yl)benzene-1,2-diamine 、 sodium t-butanolate 作用下， 以 二甲基亚砜 为溶剂， 以84 %的产率得到3-chloro-4-isobutoxy-benzonitrile
  参考文献：
  名称：

  Room‐Temperature Copper‐Catalyzed Etherification of Aryl Bromides

  摘要：

  We disclose the development of a Cu‐catalyzed C−O coupling method utilizing a new N1,N2‐diarylbenzene‐1,2‐diamine ligand, L8. Under optimized reaction conditions, structurally diverse aryl and heteroaryl bromides underwent efficient coupling with a variety of alcohols at room temperature using an L8‐based catalyst. Notably, the L8‐derived catalyst exhibited enhanced activity when compared to the L4‐based system previously disclosed for C−N coupling, namely the ability to functionalize aryl bromides containing acidic functional groups. Mechanistic studies demonstrate that C−O coupling utilizing L8 ⋅ Cu involves rate‐limiting alkoxide transmetallation, resulting in a mechanism of C−O bond formation that is distinct from previously described Pd‐, Cu‐, or Ni‐based systems. This lower energy pathway leads to rapid C−O bond formation; a 7‐fold increase relative to what is seen with other ligands. The results presented in this report overcome limitations in previously described C−O coupling methods and introduce a new ligand that we anticipate may be useful in other Cu‐catalyzed C‐heteroatom bond‐forming reactions.

  DOI：

  10.1002/anie.202400333

文献信息

• Novel oxadiazole compounds
  申请人：Hobson Adrian D.

  公开号：US20080280876A1

  公开（公告）日：2008-11-13

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  本发明揭示了新型噁二唑化合物、含有该化合物的药物组合物以及将这些化合物或组合物用作S1P家族G蛋白偶联受体的激动剂或拮抗剂，用于治疗与S1P家族受体活性调节相关的疾病，特别是通过提供有益的免疫抑制效应的疾病。
• US7834039B2
  申请人：——

  公开号：US7834039B2

  公开（公告）日：2010-11-16